Finance
French court orders Sanofi to pay $177 million for anti-competitive behaviour
Published by Global Banking & Finance Review®
Posted on September 24, 2025
2 min readLast updated: January 21, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on September 24, 2025
2 min readLast updated: January 21, 2026
A Paris court fined Sanofi $177 million for anti-competitive practices related to Plavix. The ruling affects healthcare costs and Sanofi may appeal.
(Reuters) -A Paris court on Wednesday ordered Sanofi and its Winthrop unit to pay 150.7 million euros ($177.1 million) in damages to France's national health insurance fund (CNAM) for anti-competitive practices related to its anti-clotting drug Plavix.
The ruling by the Paris appeals court stems from a 2013 decision by France's competition authority that fined Sanofi 40.6 million euros for acting against generic competitors of Plavix between 2009 and 2010.
Sanofi said it is currently analysing the grounds of the ruling and reserves the right to file an appeal before the French Supreme Court.
The appeals court found that the effects of the anti-competitive practices persisted among healthcare professionals until 2021, despite only lasting five months.
Plavix was France's most reimbursed drug in 2008, costing the healthcare system 625 million euros, the court said.
The appeals court awarded CNAM 126.2 million euros for additional reimbursement costs and pharmacy fees and 24.5 million euros in additional financial damages.
($1 = 0.8510 euros)
(Reporting by Gianluca Lo Nostro and Mathias de Rozario in Gdansk; Editing by Kirsten Donovan)
The Paris court ordered Sanofi to pay 150.7 million euros ($177.1 million) in damages.
The ruling stems from a 2013 decision by France's competition authority that fined Sanofi for anti-competitive behavior against generic competitors of Plavix.
The appeals court found that the effects of the anti-competitive practices persisted among healthcare professionals until 2021, despite only lasting five months.
The appeals court awarded CNAM 126.2 million euros for additional reimbursement costs and pharmacy fees.
Yes, Sanofi stated that it is analyzing the grounds of the ruling and reserves the right to file an appeal before the French Supreme Court.
Explore more articles in the Finance category
